This study demonstrates that dinaciclib indeed significantly enhanced the sensitivity of two typical NB cell lines, NGP and SH-SY5Y to Dox and VP-16 treatment by blocking CDK2 and CDK9 activity. The gene discussed is CDK2; the disease is neuroblastoma.